Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Isatuximab by Sanofi for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Isatuximab by Sanofi for Mantle Cell Lymphoma: Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
Isatuximab by Sanofi for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
Alemtuzumab by Sanofi for T-Cell Leukemia: Likelihood of Approval
Alemtuzumab is under clinical development by Sanofi and currently in Phase I for T-Cell Leukemia. According to GlobalData, Phase I...
Riliprubart by Sanofi for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to...
Frexalimab by Sanofi for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to...
SAR-441566 by Sanofi for Rheumatoid Arthritis: Likelihood of Approval
SAR-441566 is under clinical development by Sanofi and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II...
Isatuximab by Sanofi for Natural Killer Cell Lymphomas: Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData,...
Isatuximab by Sanofi for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Isatuximab is under clinical development by Sanofi and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
Frexalimab by Sanofi for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
Frexalimab is under clinical development by Sanofi and currently in Phase III for Relapsing Multiple Sclerosis (RMS). According to GlobalData,...
Alirocumab by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approval
Alirocumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
SAR-445611 by Sanofi for Inflammation: Likelihood of Approval
SAR-445611 is under clinical development by Sanofi and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs...
H3 mRNA/LNP Vaccine by Sanofi for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
H3 mRNA/LNP Vaccine is under clinical development by Sanofi and currently in Phase I for Influenza A Virus, H3N2 Subtype...
Venglustat malate by Sanofi for Gaucher Disease Type III: Likelihood of Approval
Venglustat malate is under clinical development by Sanofi and currently in Phase III for Gaucher Disease Type III. According to...
Fresolimumab by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approval
Fresolimumab is under clinical development by Sanofi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Sanofi's Amlitelimab?
Amlitelimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...
Risk adjusted net present value: What is the current valuation of Sanofi's Tolebrutinib?
Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Primary Progressive Multiple Sclerosis (PPMS)....
Risk adjusted net present value: What is the current valuation of Sanofi's Rilzabrutinib?
Rilzabrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
Risk adjusted net present value: What is the current valuation of Sanofi's Itepekimab?
Itepekimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....
Risk adjusted net present value: What is the current valuation of Sanofi's Venglustat malate?
Venglustat malate is a small molecule commercialized by Sanofi, with a leading Phase III program in Fabry Disease. According to...